| Patents for A61P 25 - Drugs for disorders of the nervous system (183,225) |
|---|
| 07/05/2006 | CN1262269C Compositions comprising blockers of L-DOPA renal cell transfer for treatment of Parkinson's disease |
| 07/05/2006 | CN1262268C Novel use of agmatine |
| 07/04/2006 | US7071359 Neuropathy improvers containing nitrogenous compounds as the active ingredient |
| 07/04/2006 | US7071344 Vitamin D derivatives with cyclopropyl rings in the lateral chains, a method and intermediate products for the production thereof and the utilization thereof for producing medicaments |
| 07/04/2006 | US7071335 2-pyridinyl-1-piperazine therapeutic agents useful for treating pain |
| 07/04/2006 | US7071297 Tolerogenic peptides from myelin basic protein |
| 07/04/2006 | US7071234 Administering racemic or optically pure sibutramine metabolite, or a pharmaceutically acceptable salt, solvate, or clathrate for prophylaxis or therapy |
| 07/04/2006 | US7071221 Heterocyclic oxime compounds |
| 07/04/2006 | US7071217 Substituted oxindole derivatives as tyrosine kinase inhibitors |
| 07/04/2006 | US7071213 Cannabinoid receptor ligands |
| 07/04/2006 | US7071208 β3 Adrenergic agonists |
| 07/04/2006 | US7071207 Suppression appetite; induction weight loss |
| 07/04/2006 | US7071206 Use of dimebolin to treat Alzheimer's; i.e. 2,8-dimethyl-5-[2-(6-methyl-3-pyridyl)ethyl]-2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indole or its hydrochloride (dimebolin) |
| 07/04/2006 | US7071202 Compositions and formulations of 9-nitrocamptothecin polymorphs and methods of use therefor |
| 07/04/2006 | US7071196 Piperazine derivatives as antagonists of tachykinins, including substance P and other neurokinins. |
| 07/04/2006 | US7071195 Especially amino- or amido-ethyltetralin derivatives |
| 07/04/2006 | US7071193 7-amino-2-alkylthiopteridin-4-yl-amines for the treatment of chemokine-related diseases |
| 07/04/2006 | US7071191 Non-imidazole aryloxypiperidines |
| 07/04/2006 | US7071187 Naphthyridine derivatives |
| 07/04/2006 | US7071186 Drug abuse; antiserotonine agents; central nervous system disorders; sleep disorders |
| 07/04/2006 | US7071185 Treating schizophrenia with no weight-gain side effects; 5-HT2c recptor agonist; bipolar disorder; antidepressants; anxiolytic agents; panic attack; agoraphobia; antiepileptic agents; sleep disorders; migraines; sexual dysfunction |
| 07/04/2006 | US7071183 Use of inhibitors of the renin-angiotensin system |
| 07/04/2006 | US7071179 Method of locking 1α-OH of vitamin D compounds in axial orientation |
| 07/04/2006 | US7071178 Bone disorders; osteoporosis |
| 07/04/2006 | US7071177 P-(sulfonyl) aryl and heteroarylamines as anti-inflammatory agents |
| 07/04/2006 | US7070817 Herbal composition for treating or alleviating vascular headaches, neurological conditions and neurodegenerative diseases |
| 07/04/2006 | US7070766 Delivery of physiologically active compounds through an inhalation route |
| 07/04/2006 | US7070765 condensation aerosol formed by heating a thin layer containing the ester, on a solid support to produce a vapor of the ester, and condensing the vapor; less than 10% ester degradation products by weight, and a Mass median aerodynamic diameter of less than 5 microns. |
| 07/04/2006 | US7070764 Delivery of analgesics through an inhalation route |
| 07/04/2006 | US7070763 Delivery of diphenhydramine through an inhalation route |
| 07/04/2006 | US7070762 Delivery of analgesics through an inhalation route |
| 07/04/2006 | US7070761 Aerosols; heating, vaporization, cooling |
| 07/04/2006 | CA2462452C Pharmaceutical composition of 2-(4-isobutylphenyl) propionic acid |
| 07/04/2006 | CA2404848C Indole carboxylic acids as thyroid receptor ligands |
| 07/04/2006 | CA2364719C 2-aminopyridines containing fused ring substituents |
| 07/04/2006 | CA2332066C Tetrazole compounds as thyroid receptor ligands |
| 07/04/2006 | CA2279063C A pharmaceutical composition for the prevention and treatment of diseases of cognitive dysfunction in a mammal |
| 07/04/2006 | CA2233285C Pyrazolopyrimidines as crf receptor antagonists |
| 07/04/2006 | CA2130797C 2,3,4,5-tetrahydro-1h-3-benzazepines having anti-psychotic activity, and synthesis of .alpha.-substituted-arylacetamides |
| 06/29/2006 | WO2006069294A1 1-aminocyclohexane-derivatives for the treatment of multiple sclerosis emotional lability and pseudobulbar affect |
| 06/29/2006 | WO2006069293A2 Composition comprising n-acetylcysteine and further pain or anti- inflamm medications |
| 06/29/2006 | WO2006069277A1 TRICYCLIC δ-OPIOID MODULATORS |
| 06/29/2006 | WO2006069276A2 TRICYCLIC ō-OPIOID MODULATORS |
| 06/29/2006 | WO2006069275A1 Tricyclic delta-opioid modulators |
| 06/29/2006 | WO2006069202A2 Compositions comprising anti-igf-i receptor antibodies and methods for obtaining said antibodies |
| 06/29/2006 | WO2006069097A2 Nicotinic alpha-7 receptor ligands and preparation and uses thereof |
| 06/29/2006 | WO2006068932A2 Rapamycin analogues and the uses thereof in the treatment of neurological, proliferative, and inflammatory disorders |
| 06/29/2006 | WO2006068904A1 Tetrahydroquinoline analogues as muscarinic agonists |
| 06/29/2006 | WO2006068594A1 HETEROCYCLIC MCHr1 ANTAGONISTS AND THEIR USE IN THERAPY |
| 06/29/2006 | WO2006068593A1 New benzothiazolesulfonamides |
| 06/29/2006 | WO2006068592A1 New benzothiazolecarboxamides |
| 06/29/2006 | WO2006068591A1 Novel pyrazole derivatives and their use as modulators of nicotinic acetylcholine receptors |
| 06/29/2006 | WO2006068326A1 Novel polypeptide and the use thereof |
| 06/29/2006 | WO2006068199A1 Metabolically stable 3-oxy-1,2,4-triazole derivatives |
| 06/29/2006 | WO2006068155A1 Agent for reconstructing neural network comprising chinese medicine formulation and method of reconstructing neural network |
| 06/29/2006 | WO2006068058A1 Crystal and salt of 1-cyclopropylmethyl-4-[2-(3,3,5,5)-tetramethylcyclohexyl)phenyl]piperazine |
| 06/29/2006 | WO2006067611A1 Methods of modulating the activities of alpha7 nicotinic acetylcholine receptor |
| 06/29/2006 | WO2006067605A1 Stable pharmaceutical compositions of tiagabine and processes for their preparation |
| 06/29/2006 | WO2006067565A2 Truncated gabab receptor and methods of use thereof |
| 06/29/2006 | WO2006067529A1 Piperidine and azetidine derivatives as glyt1 inhibitors |
| 06/29/2006 | WO2006067496A1 Combination of sabcomeline with a neuroleptic agent to treat psychotic disorders |
| 06/29/2006 | WO2006067494A1 Sabcomeline alone or combined with a mood stabilising or antimanic agent to treat bipolar disorders |
| 06/29/2006 | WO2006067443A1 Therapeutic agents |
| 06/29/2006 | WO2006067437A1 Oxygen containing heterocycles as glycine transporter inhibiting compounds |
| 06/29/2006 | WO2006067430A1 2-amino-1-phenylethylcarboxamide derivatives |
| 06/29/2006 | WO2006067362A1 Treatment for severe melancholic depression with epa |
| 06/29/2006 | WO2006067141A1 Cladribine regimen for treating multiple sclerosis |
| 06/29/2006 | WO2006067139A1 Triazolone, tetrazolone and imidazolone derivatives for use as alpha-2c adrenoreceptor antagonists |
| 06/29/2006 | WO2006066968A1 Pyridine compounds for the treatment of prostaglandin mediated diseases |
| 06/29/2006 | WO2006066756A1 Chroman derivatives and uses thereof in the treatment of cns disorders |
| 06/29/2006 | WO2006066748A1 Tetralin and indane derivatives and uses thereof as 5-ht antagonists |
| 06/29/2006 | WO2006066745A1 Tetralin and indane derivatives and uses thereof |
| 06/29/2006 | WO2006066512A1 Pyrimidinone compounds, their preparation and use thereof |
| 06/29/2006 | WO2006066362A1 Methods of treating pain |
| 06/29/2006 | WO2006066361A1 Method of treatment or prophylaxis |
| 06/29/2006 | WO2006054298A3 Glycogen synthase kinase-3 inhibitors |
| 06/29/2006 | WO2006017836A3 2-amino-quinazoline derivatives useful as inhibitors of beta-secretase (bace) |
| 06/29/2006 | WO2006017188A3 Memantine as adjunctive treatment to atypical antipsychotics in schizophrenia patients |
| 06/29/2006 | WO2006016262A8 Combination of a selective noradrenaline reuptake inhibitor and a pdev inhibitor |
| 06/29/2006 | WO2006000222A3 The combination of an antipsychotic and a glycine transporter type i inhibitor for the treatment of schizophrenia |
| 06/29/2006 | WO2005115471A8 Methods and compositions for treatment of nicotine dependence and dementias |
| 06/29/2006 | WO2005115396A3 Combination of atomoxetine and a 5t1a receptor agonist for treating adhd and other disorders |
| 06/29/2006 | US20060142566 Enantioselective process for the preparation of both enantiomers of 10,11-dihydro-10-hydroxy-5h-dibenz[b,f]azepine-5-carboxamide and new crystal forms thereof |
| 06/29/2006 | US20060142396 Use of GABA agonists for the treatment of spastic disorders, convulsions, epilepsy, and neuroprotection |
| 06/29/2006 | US20060142388 2-Aminobicyclo[3.1.0]hexane-2,6-dicarboxylic acid derivative |
| 06/29/2006 | US20060142372 For use as antidepressants, anxiolytics, antipsychotics, neuroleptics and/or antihypertonics, have actions on the central nervous system, in particular 5-HT reuptake-inhibiting actions, in that they influence serotoninergic transmission, they have a strong affinity to the 5-HT1A receptors |
| 06/29/2006 | US20060142357 Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 |
| 06/29/2006 | US20060142333 e.g. N-(1-Methyl-1,2,3,4-tetrahydroquinolin-7-yl)-1,1'-biphenyl-4-carboxamide; capsaicin recepor antagonist; analgesic; neuropathic, postoperative, postrheumatoid arthritic, back, cancer pain, neuralgia, dental pain, headache, migraine, diabetic and HIV-related neuropathy |
| 06/29/2006 | US20060142331 of serotonin, dopamine and noradrenaline receptors; e.g. 2-(2,3-Dichlorophenoxymethyl)-8-methyl-3-(3-chlorophenyl)-8-aza-bicyclo[3.2.1]octane; antidepressant. anxiolytic agent; eating, bipolar disorders, obesity; drug, tobacco, alcohol abuse; neurodegenerative diseases |
| 06/29/2006 | US20060142330 e.g. 4-chloro-3-(phenylsulfonyl)-1-(piperidin-4-ylmethyl)-1H-pyrazolo[4,3-b]pyridineI; antidepressant, anxiolytic agent, cognition activator; Alzheimer's and attention deficit disorder, schizophrenia, obsessive compulsive disorders, |
| 06/29/2006 | US20060142329 Substituted fused N-heteroaryl compounds such as imidazo[1,5a]- or [1,2s]pyridines, e.g., 3-[3-(Pyrrolylphenoxy-2-hydroxypropyl)aminoalkyl]imidazo[1,5-a]pyridine derivatives, especially HCl salts; treating obesity and type 2 diabetes |
| 06/29/2006 | US20060142328 Beta 3 adrenergic agonists |
| 06/29/2006 | US20060142327 Beta 3 adrenergic agonists |
| 06/29/2006 | US20060142326 Use of pyrazolopyridines for the treatment of cognitive deficits |
| 06/29/2006 | US20060142317 3-Substituted 3,4-dihydro-thieno[2,3-d]pyrimidin-4-one derivatives, production and use thereof |
| 06/29/2006 | US20060142314 2-substituted-4-(indazol-5-ylamino)-6,7-dimethoxyquinazoline compounds; use treating hypertension, atherosclerosis, restenosis, cerebral ischemia or vasospasm, neurodegeneration, spinal cord injury, cancer, thrombotic disorders, asthma, glaucoma, osteoporosis or erectile dysfunction |
| 06/29/2006 | US20060142313 2-substituted-4-(indazolamino)quinazoline compounds; use treating hypertension, atherosclerosis, restenosis, cerebral ischemia or vasospasm, neurodegeneration, spinal cord injury, cancer, thrombotic disorders, asthma, glaucoma, osteoporosis or erectile dysfunction |
| 06/29/2006 | US20060142309 8-Heteroaryl xanthine adenosine A2B receptor antagonists |
| 06/29/2006 | US20060142302 Chemical compounds |
| 06/29/2006 | US20060142296 4(Phenyl-piperazinyl-methyl) benzamide derivatives and their use for the treatment of pain or gastrointestinal disorders |